Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80
Organisation › Details

Moderna Inc. (Nasdaq: MRNA)

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators. Headquartered in Cambridge, Mass., with a European headquarters in Basel, Switzerland, Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the past five years. *

 

Period Start 2018-08-01 renamed
  Group Moderna (Group)
  Predecessor Moderna Therapeutics Inc.
Products Industry mRNA-based drug
  Industry 2 mRNA technology
Person Person Bancel, Stéphane (Moderna 2011– CEO before bioMérieux 201010 CEO + Eli Lilly)
     
Region Region Cambridge, MA
  Country United States (USA)
  Street 200 Technology Square
  City 02139 Cambridge, MA
  Tel +1-617-714-6500
    Address record changed: 2020-12-02
     
Basic data Employees E: 501 to 1,000 (2020-02-12)
  Currency USD
  Annual sales 60,209,000 (revenue, total, consolidated (2019) 2019-12-31)
  Profit -514,021,000 (2019-12-31)
  Cash 1,103,000,000 (2019-12-31)
     
    * Document for �About Section�: Moderna, Inc.. (9/16/20). "Press Release: Moderna Announces First Commercial Organization Outside North America in Switzerland". Cambridge, MA.
     
   
Record changed: 2021-06-02

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Moderna (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture [iito] Back into Ad 650x80px




» top